TRANSFORM — Lisocabtagene Maraleucel Versus Standard Care as Second-Line Therapy for Large B-Cell Lymphoma (TRANSFORM)

Phase 3 · 2022 · Diffuse Large B-Cell Lymphoma

Design

Randomized trial of lisocabtagene maraleucel versus standard second-line care (salvage immunochemotherapy and autologous stem-cell transplant in responders).

Population

Large B-cell lymphoma refractory to or relapsing within 12 months of first-line therapy.

Primary Endpoint

event-free survival (EFS)

Key Result

EFS 10.1 vs 2.3 months (HR 0.35) favoring lisocabtagene maraleucel over standard care.

Guideline Impact

NCCN category 1 lisocabtagene maraleucel for primary refractory or early-relapsing large B-cell lymphoma